Vittoria A, Messa G L, Frigerio C, Celasco G, Auteri A
Istituto di Patologia Speciale Medica, University of Siena, Italy.
Int J Tissue React. 1988;10(4):261-6.
The profibrinolytic activity of orally administered Mesoglycan was evaluated in 18 patients affected by impaired plasma fibrinolytic activity. Mesoglycan was administered by a single oral dose of 24, 48 or 72 mg on 1 day, and by repeated doses of 48 mg twice a day for 9 consecutive days. After the single administration all the fibrinolytic parameters were significantly and positively influenced with an order of magnitude and a duration of effects proportional to the dose employed. After the repeated administration, a constant and reproducible activation of the fibrinolytic system was observed without any interference with haemocoagulative parameters. These results confirm that Mesoglycan is endowed with a relevant profibrinolytic activity in man after oral administration. The pharmacological activity of Mesoglycan could possibly involve the liberation of a certain amount of plasminogen tissue activator.
在18名血浆纤溶活性受损的患者中评估了口服葡糖胺聚糖的促纤溶活性。葡糖胺聚糖于第1天单次口服给予24、48或72mg，或连续9天每天两次重复给予48mg。单次给药后，所有纤溶参数均受到显著的正向影响，其影响程度和持续时间与所用剂量成正比。重复给药后，观察到纤溶系统持续且可重复的激活，而对血液凝固参数无任何干扰。这些结果证实，葡糖胺聚糖口服给药后在人体内具有显著的促纤溶活性。葡糖胺聚糖的药理活性可能涉及一定量纤溶酶原组织激活剂的释放。
